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   Supplementary Tables 
Supplementary Table 1: Genotype QC for samples used in exome analyses. 
Cases GS:SFHS 
Controls 
1958BC 
Controls* 
OXBB Controls* GoDARTS 
Controls* 
Initial sample 3487 1032 - - - 
Samples failing stage 1 QC: pre zCall 
Call rate < 90% 34 1 - - - 
Sex mismatches 18 2 - - - 
Heterozygosity outliers (common SNPs MAF ≥ 1%) 41 3 - - - 
Heterozygosity outliers (rare SNPs MAF < 1%) 28 6 - - - 
Call rate < 98% 43 46 - - - 
Duplicates (PI_HAT > 0.95) 56 0 - - - 
PCA outliers (+/- 3SD of the mean) 12 2 - - - 
Samples with excess number of singletons SNPs (> 50) 15 6 - - - 
Inconsistency with GWAS data 1 0 - - - 
XY-intensity outliers (+/- 4SD of the mean) 12 0 - - - 
Samples passing pre zCall QC 3302 976 1456 1822 635 
Samples failing stage 2 QC: post zCall 
Call rate  < 99% 0 0 0 0 0 
Heterozygosity outliers 76 15 27 52 11 
Final Samples Passing both QC stages 3226 961 1429 1770 624 
*Stage 1 QC and recalling of genotypes using zCall carried out for 1958BC, OXBB and GoDARTs controls within UK exome chip consortium.
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Supplementary Table 2: Top associations in exome analysis and meta-analysis of severity of airflow limitation. 
a. SNPs with P<10-4 in either the pack-years adjusted, or unadjusted discovery analyses
Severity of  airflow limitation, 
adjusted for pack-years (n=2517) 
Unadjusted  analysis of severity of 
airflow limitation (n=3226) 
UK BiLEVE  pack-years adjusted 
analysis (n=4231 ) 
Meta-analysis of 
discovery and UK 
BiLEVE pack-year 
adjusted analyses. 
rs no. CHR Position 
Coded 
Allele 
Gene 
MAF 
(MAC) 
Beta P 
MAF 
(MAC) 
Beta P 
MAF 
(MAC) 
Beta P Beta P 
rs77108843 19 1828148 A 
REXO1 
(nonsynonymous) 
0.50% 
(25) 
13.37 7.44×10-5 
0.59% 
(38) 
12.09 1.18×10-5 
0.82% 
(63) 
-0.741 0.590 0.057 0.396 
rs59035258 8 65527669 T 
CYP7B1 
(nonsynonymous) 
3.7% 
(187) 
4.178 8.75×10-4 3.6% (232) 4.793 2.11×10-5 
4.1% 
(314) 
-0.224 0.721 0.386 0.306 
rs117991621 12 96379884 T 
HAL 
(nonsynonymous) 
0.56% 
(28) 
10.92 6.19×10-4 
0.56%3
(36) 
12.02 2.26×10-5 
0.50%
(42) 
-1.221 0.569 0.133 0.423 
rs28929474 14 94844947 T 
SERPINA1 
(nonsynonymous) 
2.2% 
(109) 
-5.053 1.30×10-3 2.0% (127) -6.165 2.83×10-5 
2.2% 
(183) 
-1.53 0.061 -2.583 2.73 x10-3 
rs11749 1 38023316 T 
DNALI1 
(nonsynonymous) 
24.1% 
(1212) 
-1.57 3.99×10-3 
24.3% 
(1565) 
-1.967 4.30×10-5 
25.1% 
(2123) 
-0.3228 0.235 -1.789 0.027 
rs147487857 15 41247629 G 
CHAC1 
(nonsynonymous) 
1.3% (63) -8.895 3.27×10-5 1.3% (81) -5.619 3.19×10-3 
1.5% 
(123) 
0.2003 0.840 -0.597 0.163 
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Supplementary Table 3: Sensitivity analysis of SNPs identified in either the discovery, or meta-analyses of COPD risk.  Results for original analyses, and for analyses where cases restricted to 
include only those with known irreversible airflow limitation 
a. SNPs identified in discovery analyses
Discovery pack-years 
adjusted analysis (2517 
cases, 3889 controls) 
Discovery pack-years 
adjusted analysis (1365 
COPD cases with 
reversibility testing, 3889 
controls) 
Discovery unadjusted 
analysis (3226 cases, 
4784 controls) 
Discovery unadjusted 
analysis (1398 COPD cases 
with reversibility testing, 
4784 controls) 
rs no. CHR Position Coded 
Allele 
Gene OR P* OR P* OR P* OR P* 
rs3813803 1 28282292 C SMPDL3B 
(nonsynonymous) 
1.37 2.41x10-6 1.46 5.18 x10-6 1.288 2.11 x10-6 1.382 2.98 x10-6 
rs17368582 11 102738075 C MMP12 
(synonymous) 
0.767 3.22 x10-3 0.673 1.08 x10-3 0.712 5.01 x10-6 0.6567 2.35 x10-5 
rs3827522 12 42853871 A PRICKLE1 
(nonsynonymous) 
0.184 1.39 x10-3 0.272 1.08 x10-3 0.123 1.03 x10-7 0.1836 1.43 x10-4 
rs8034191 15 78806023 C near AGPHD1 
(intergenic) 
1.374 2.42 x10-7 1.42 8.14 x10-6 1.364 1.18 x10-9 1.414 1.33 x10-7 
rs7269297 20 49576664 G MOCS3 
(nonsynonymous) 
0.251 3.08 x10-6 0.276 4.05 x10-4 0.423 3.98 x10-4 0.4502 0.0118 
b. SNPs identified in meta-analyses
Discovery pack-years 
adjusted analysis (2517 
cases, 3889 controls) 
Discovery pack-years 
adjusted analysis (1365 
COPD cases with 
reversibility testing, 3889 
controls) 
Discovery unadjusted 
analysis (3226 cases, 
4784 controls) 
Discovery unadjusted 
analysis (1398 COPD cases 
with reversibility testing, 
4784 controls) 
rs no. CHR Position Coded 
Allele 
Gene OR P* OR P* OR P* OR P* 
rs1828591 4 145480780 A 
GYPA / HHIP 
(intergenic) 
0.9167 0.153 0.8727 0.08661 0.919 0.093 0.8821 0.05665 
rs4896582 6 142703877 A GPR126 0.8594 0.018 0.8676 0.08605 0.864 5.95 x10-3 0.8702 0.04272 
rs140549288 10 91099466 C 
IFIT3 (exonic), LIPA 
(intronic) 
2.156 0.037 2.554 0.06401 1.823 0.057 2.211 0.04798 
*P-values in bold significant at P<10-5 level
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        Supplementary Figures 
Supplementary Figure 1: Quantile-quantile plots for analyses of COPD risk with (right) and without (left) pack-years adjustment. SNPs with MAF>0.05% only. 
λ=1.013 λ=1.054 
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Supplementary Figure 2: Quantile-quantile plots for analyses of severity of airflow limitation with (left) and without (right) pack-years adjustment. Plots include all SNPs passing genotype QC.
λ=1.130 λ=1.122 
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Supplementary Figure 3: A) Manhattan for severity of airflow limitation analysis, adjusted for pack-years smoking (all 
SNPs passing genotype QC). B)Manhattan for severity of airflow limitation analysis without adjustments for pack-years 
smoking (all SNPs passing genotype QC). 
A) 
       B)
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Supplementary Figure 4: Quantile-quantile plots for meta-analysis of COPD risk in discovery exome analysis and UK BiLEVE 
samples. 
Supplementary Figure 5: Quantile-quantile plots for meta-analysis of severity of airflow limitation in discovery exome analysis 
and UK BiLEVE samples 
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Supplementary Figure 6: Manhattan plot for meta-analysis of severity of airflow limitation in discovery exome analysis and UK 
BiLEVE samples 
SERPINA12 
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Supplementary Figure 7: Comparison of effect estimates of discovery case-control analysis of COPD risk where the cases were restricted to only include those with known irreversible airflow 
obstruction, versus the analysis including all COPD cases. Highlighted are the effect estimates of the two SNPs we report in novel regions (rs7269297 in MOCS3 and rs140549288 in IFIT3). 
MOCS3
IFIT3 
MOCS3 
IFIT3 
B. Discovery analysis of COPD risk, adjusted for pack-years A. Discovery analysis of COPD risk, without  adjustment for pack-years 
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Supplementary Figure 8: Region plots for novel regions associated with COPD risk (A & B) and percent predicted FEV1 in 
COPD cases (C). 
A. rs7269297 in MOCS3¸ 
associated with COPD risk. 
B. rs140549288 in IFIT3¸ 
associated with COPD risk. 
C. rs140198372 in MOCS3¸ 
associated with percent 
predicated FEV1  in COPD 
cases. 
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      Supplementary methods 
Case Collections 
Gedling: The Gedling cohort is a general population sample of adults aged 18 to 70 years, recruited 
in Nottingham in 1991 (n=2,633) in a cross-sectional study of the relationship between diet, asthma, 
and COPD. Subjects were followed-up in 2000 (n=1346), where they had blood samples taken for 
DNA extraction (Source Biosciences, UK), completed questionnaires on respiratory symptoms, 
smoking, and other variables, and had pre-bronchodilator FEV1 and FVC measurements taken using a 
calibrated dry bellows spirometer (Vitalograph, Buckingham, UK), recording the best of three 
satisfactory attempts (1, 2). 
EU COPD Gene Scan (EUCOPD): The COPD exome chip study utilised EUCOPD samples recruited 
from Bristol and Edinburgh. All samples had a clinical diagnosis of stable COPD, with FEV1/FVC < 70%, 
percent predicted FEV1 ≤ 70%, according to the Crapo et al. reference equations (3) , no significant 
reversibility on bronchodilation , and at least 20 pack-years smoking history. Patients were excluded 
from the study if they had a diagnosis of asthma, established obstructive syndrome, lung cancer, a 
history of atopy, known alpha-1 antitrypsin deficiency, or a serum alpha-1 antitrypsin level of 
<1.0g/L, or had experienced an acute exacerbation in the 4 weeks prior to recruitment. (4) 
Generation Scotland: Scottish Family Health Study (GS:SFHS): 
GS:SFHS is a family-based general population study of approximately 24,000 Scottish individuals 
aged 18–98 years, recruited through general practices between 2006 and 2011. At baseline, 
participants had demographic and lifestyle factors collected through questionnaires, blood and 
saliva samples were collected for DNA extraction and several clinical measures were taken, including 
spirometry (5). Spirometry was performed three times, without nose clips using the Ndd Easy One 
Spirometer (Model 2001). The maximum values of FVC and FEV1 were used in the analyses. 
 Participants were excluded from spirometry testing if <12 or >24 weeks pregnant; had stroke or 
heart attack in previous year; used inhaler and did not have it with them; had collapsed lung, flu, 
severe cold, chest infection or any surgery in previous month; had detached retina in previous 3 
months. 
British Regional Heart Study (BRHS):The BRHS includes 7735 men, aged 40-59 who were recruited 
from 24 towns across the UK between 1978 and 1980, with a follow-up assessment in 1998-2000 
(n=4252). Participants periodically completed questionnaires which including questions on lifestyle, 
medication use and respiratory symptoms. At baseline and follow-up examinations, participants had 
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lung function measurements taken (6). Measures used in this study were from the follow-up 
assessment, where a minimum of 3 spirometry measurements were obtained standing and without 
noseclips, using a Vitalograph Compact II instrument (Vitalograph Ltd, Buckingham,UK). FEV1 and 
FVC were recorded for the best test, which was defined in accordance with American Thoracic 
Society recommendations(7). Blood samples for DNA extraction were taken at the follow-up 
examination (6). 
British Women’s Health and Heart Study (BWHHS): The BWHHS recruited 4286 women aged 60-79 
between 1999 and 2001. Participants were recruited from 23 centres in the UK (22 centres common 
with BRHS study) and were matched in terms of town and age to BRHS participants.  At baseline 
Clinical measurements were made on 3995 with 3923 providing some blood. DNA was also extracted 
for genotyping from the blood samples.  Baseline data collection took place between April 1999 and 
March 2001. Participants also completed questionnaires on lifestyle and medical history. (8) 
Participants performed spirometry measurements, using digital meter Vitalograph, until three 
reproducible blows were achieved(within 5% of maximum FVC produced). The blow with the highest 
sum of FVC and FEV1 was used in the analyses. 
UK COPD Cohort (UKCOPD): COPD subjects were recruited from five UK centres based on physician- 
and spirometry-defined COPD (FEV1/FVC <70%; FEV1 <80%), Caucasian, >40 yr old, smokers with 
>10 pack-yr history (9). Ethical approval was obtained from the Multicenter Research Ethics 
Committee (MREC/99/4/001) and informed consent from all subjects was obtained. 
Hertfordshire Cohort Study (HCS):HCS recruited men and women from Hertfordshire, born between 
1931 and 1939. At baseline, study participants completed questionnaires, including demographics, 
medical history, and details of respiratory symptoms. 2997 recruited individuals attended a clinic, at 
which they had lung function measurements and blood taken for DNA extraction (10). Spirometry 
measurements were taken three times with participants seated and without noseclips, using a Micro 
Spirometer (Micro Medical Ltd). The highest FEV1 and FVC values from satisfactory manoeuvres (not 
necessarily from the same blow) were used in the analyses. 
COPD-BEAT (Biomarkers to target Antibiotic & Systemic Corticosteroid therapy in COPD 
exacerbations): Recruited individuals with COPD in two 1 year studies in series with part 1 a one 
year observational study and part 2 where subjects were randomised to either standard care or 
targeted care following part 1. Subjects in the targeted therapy arm were further randomised to 
receive either prednisolone or matching placebo determined by the biomarker- the blood eosinophil 
count. Subjects were assessed at 3 monthly stable visits, at exacerbation onset and 2 and 6 week 
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recovery. Assessments included symptoms, health status, airway inflammation, lung function, 
microbiology and virology.  
Nottingham COPD Study (NottCOPD): Recruited individuals between 40-85 years of age who had 
smoked at least 10 pack years and were Caucasian. A diagnosis of COPD was made on basis of 
clinical assessment and spirometry when the subject was at clinical stability (> 4 weeks  from any 
exacerbation or change in medication). Spirometry was performed (pre and post bronchodilator) on 
a Micromedical MK6 (Micro Medical Ltd, UK) with the best of three satisfactory and repeatable 
attempts used in the analysis (11). Blood samples for DNA extraction were taken at the same visit. 
Nottingham Smokers: The Nottingham Smokers cohort recruited individuals in Nottingham who 
were Caucasian, over 40 years of age and with at least 10 pack years smoking history. Participants 
had spirometry measured at enrolment using a MicroLab ML3500 spirometer (Micro Medical Ltd, 
UK) with the best of three satisfactory attempts used in the analyses. 
English Longitudinal Study of Aging (ELSA):ELSA is a longitudinal study of individuals aged over 50 
and their partners, who had previously responded to the Health Survey of England between 1998 
and 2001. Individuals were recruited in 2002-3, with participants having follow-up interviews every 
two years. Spirometric measures used in these analyses were taken at the third wave of interviews 
(2006-2007). 
GoTARDIS Study: The GoTARDIS study recruited individuals with COPD in Dundee, Scotland who 
were being managed by the community respiratory care network, through the TARDIS database. All 
COPD patients in Dundee attend annual meetings at their GP practice with a respiratory nurse, 
where spirometry, disease activity and treatment information are recorded and stored in the central 
TARDIS database. Patients were recruited through their General Practitioners and provided consent 
for linkage of their genetic to their medical records. Participants provided saliva samples for DNA 
extraction using Oragene saliva collection kits. 
Genotype calling and Quality Control (QC) of exome array genotype data 
Genotypes were called using Illumina’s Gencall algorithm in Genomestudio (12), then SNPs and 
samples with >90% missing data were removed. Subsequently, samples with a call rate < 98%, 
heterozygosity rate>3 standard deviations (SD) from mean (calculated separately using SNPs with 
MAF>=1% and SNPs with MAF<1%), gender mismatches, and duplicates were excluded. Additionally, 
samples with an excess of singleton SNPs (those who were the only individual to have the minor 
allele for >50 SNPs), and samples whose mean probe intensity across all autosomal SNPs was 
outlying were also excluded. Ancestry principal components analysis (PCA) was carried out using 
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EIGENSTRAT(13), with a subset of Linkage disequilibrium (LD) pruned HapMap 3 CEU SNPs with 
MAF>1% and call rate>99%; any individuals >4SD from the sample mean for either of the first two 
principal components were excluded. Additionally, SNPs were excluded if they showed differential 
rates of missingness in cases and GS:SFHS controls (P<10-4). 
Following these exclusions, missing genotypes were recalled using zCall (14) and a second stage of 
QC was carried out. SNPs with call rate<99% or which deviated from Hardy Weinberg Equilibrium 
(P<10-4) were excluded, along with samples with call rate < 99%, and heterozygosity outliers (>3SD 
from mean). To eliminate variants that were subject to genotyping batch effects, we tested for 
associations between genotype and sample collection, separately in cases and controls; any SNP 
showing association (P<10-5) was excluded. 
Discovery exome gene-based analysis 
Variants were annotated to genes using ANNOVAR (15) on the basis of the GRCh37/hg19 database 
and all exonic variants were included in the analyses. Analyses of COPD risk and severity of airflow 
limitation were undertaken using SKAT-O (16), with covariate adjustments analogous to the single 
variant analyses and using default beta distribution weightings (weight for jth variant: 
β(𝑀𝐴𝐹𝑗; 1, 25)). We filtered gene-based results to only include genes with at least two SNPs with a 
MAF<5%, and with a cumulative MAF>0.05%. To further evaluate notable gene based signals, we 
utilised a “drop-one” analysis. This involved recalculating the SKAT-O P-value when individual SNPs 
are sequentially excluded from the test. If the SKAT-O P-value was considerably attenuated by the 
removal of a particular SNP, this would indicate that the SKAT-O signal was likely to be largely 
influenced by that individual SNP, rather than variants within that gene as a whole. Applying a 
Bonferroni correction for the number of genes tested results in a significance level of P<3.5x10-6; we 
took forward genes with P<10-5 for replication analyses in UK BiLEVE. 
Custom content design, genotyping and QC of genotype data 
All 3487 cases and 1032 GS:SFHS controls were genotyped using the Illumina Human Exome 
BeadChip, with additional custom content, selected as follows:53,300 SNPs were selected as 
showing association with FEV1 and/or FEV1/FVC with P<0.01 from the discovery stage of a meta-
analysis of 48,000 individuals (17). Each SNP was assigned the P value for the trait with which it 
showed the strongest association and SNPs were then ranked by significance. The SNPs were then 
LD pruned such that for SNPs with P<10-4, all SNP within 500kb and with r2>0.5 with the most 
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significant SNP were removed and for SNPs with 10-4<P<0.01, SNPs within 500kb and with r2>0.2 
were removed. This method of LD pruning was intended to result in higher coverage of SNPs in 
regions showing slightly stronger evidence of association. Sample exclusions were carried out 
identically to the exome analysis. SNP exclusions were undertaken to remove those with a call rate < 
95%, deviated from HWE (P<10-4) or were monomorphic. 
Additional controls for the custom content analyses came from 1958BC and Busselton Health Study 
(BHS) genotyped using the Affymetrix 500k, or Illumina 550k, 660k, 1M 610-Quad or 660w-Quad SNP 
genotyping platforms and then imputed to the 1000 Genomes Project Phase 1 (1000G) reference 
panel (18). Both the 1958BC and BHS controls genotype data were phased using MACH v.1.0.18 (19), 
with 1958BC imputed using Minimac v.2012.11.16 and BHS imputed using Minimac v.2012.10.3 (20). 
Post-imputation, SNPs were excluded if they had low imputation quality (R2<0.3) in either the 
1958BC or BHS data. We additionally undertook control set comparisons for all custom content SNPs 
to identify possible batch effects (comparison of GS:SFHS controls vs all other controls). We 
subsequently removed any SNP showing association to control set with P<0.01.  The 1958BC and 
BHS control samples used in these analyses are summarised in Supplementary Table 4. 
Supplementary Table 4: Characteristics of the control samples used in the Custom Content analyses (Characteristics of 
cases and GS:SFHS controls shown in Table 1 of manuscript). 
Sample Collection 
n 
Sex Age 
Percent 
Predicted FEV1 
FEV1/FVC Pack-years 
Male, n (%) Mean (SD) Mean (SD) Mean (SD) 
Samples with 
data (n) 
Mean (SD) 
Controls (Custom Content analysis: total n=3262, with pack-years n=2252) 
British 1958 Birth 
Cohort (1958BC) 
1585 875 (55.2%) 44 (0) 
100.13 (13.40) 0.810 (0.060) 1160 14.4 (13.35) 
Busselton Health Study 
(BHS) 
716 403 (56.3%) 56.53 (11.26) 
99.43 (11.38) 0.78 (0.044) 131 34.39 (30.91) 
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Custom content single variant analyses 
Single variant associations with the custom content SNPs and both COPD risk and severity of airflow 
limitation were undertaken equivalently to the exome analyses. The custom content analysis 
included only SNPs with a priori evidence of association with lung function, thus we used a threshold 
of P<10-3 for selecting SNPs for replication analyses in UK BiLEVE. We set a Bonferroni corrected 
significance level for replication, for the number of SNPs in novel regions taken forward to 
replication (P<0.0125 for analysis of COPD risk; P<0.010 for analysis of airflow limitation severity). 
Replication and meta-analysis with UK BiLEVE data 
The 4231 cases with airflow limitation indicative of COPD and 8979 controls from UK BiLEVE 
contributing to the meta-analysis, were selected based on their % predicted FEV1 values, calculated 
using reference equations derived using healthy never smokers in the whole of UK Biobank. For 
association testing, percent predicted FEV1 was recalculated using the NHANES III spirometric 
reference equations (21)  for consistency with the exome discovery analyses. All selected COPD 
cases met GOLD 2 criteria (FEV1/FVC<0.7 and % predicted FEV1<80%) under both reference 
equations. 
SNP associations with risk of COPD were carried out using a logistic regression model, implemented 
in Plink v1.07 (22) adjusting for age, sex and pack-years and assuming an additive genetic model. In 
the analysis of severity of airflow limitation, associations with untransformed percent predicted 
FEV1, in cases were tested using a linear regression model, with adjustment for pack-years. 
The genomic inflation factor (λ) was calculated for the exome array and UK BiLEVE analyses and 
where λ>1, genomic control was applied, adjusting the standard errors of effect estimates 
accordingly. All SNPs were oriented to the same strand, with consistent coded alleles. Effect 
estimates and standard errors were combined across the two analyses using an inverse-variance–
weighting meta-analysis. λ was calculated for the pooled effect estimates and genomic control was 
applied again where λ>1. Meta-analysis statistics and figures were produced using R version 3.1.1. 
For the replication of associations identified in the discovery exome analyses, a look-up of the UK 
BiLEVE and meta-analysis results was undertaken. Replication of associations identified through the 
custom content analyses was undertaken in the same way, where SNPs were genotyped in the UK 
BiLEVE samples. Where a SNP was not directly genotyped, additional analyses was carried out using 
imputed data: UK BiLEVE samples were imputed to a combined 1000G (18) and UK10K Project (23) 
reference panel. Following imputation, SNPs were excluded if they had imputation INFO score ≤0.5 
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or minor allele count (MAC)<3. Associations were carried out for relevant SNPs using SNPTEST 
v2.5b4 (24). 
      Supplementary Results 
Discovery exome gene-based analysis 
In the gene-based analyses of COPD risk, PRICKLE1 was the only gene to reach the P<10-5 significance 
level (P=1.968×10-6, unadjusted analysis). The SKAT-O test included three SNPs within this gene, 
however “drop-one” analyses showed the signal to be entirely driven by rs3827522 (MAF=0.4%), the 
SNP identified in the single variant analysis (Supplementary Table 5). The analyses of severity of 
airflow limitation identified no associated genes with P<10-5. 
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Supplementary Table 5: Risk of COPD single variant association results of SNPs included in SKAT-O test of PRICKLE1 (SKAT-O test P-value= 1.968×10-6) 
Risk of  COPD with pack-years adjustment Unadjusted  analysis of risk of  COPD Drop-one result 
MAF (MAC) Association result MAF (MAC) Association result 
rs no. 
Coded 
Allele 
Cases 
(n=2517) 
Controls 
(n=3889) 
OR P 
Cases 
(n=3226) 
Controls 
(n=4784) 
OR P 
SKAT-O Analysis 
utilising all SNPs in 
PRICKLE1 
P-value of SKAT-O Analysis 
if SNP removed 
rs3827522 A 0.22% (11) 0.35% (27) 0.628 1.38×10-3 0.22% (14) 0.0048 (46) 0.123 1.03×10-7 Unadjusted 
P=1.968×10-6
Pack-years adjusted 
P=2.086×10-3
unadjusted:P=0.0484; 
adjusted: P=0.0258 
rs146199468 G 0.02% (1) 0.00% (0) - - 0.02% (1) 0.00 (0) - - 
unadjusted:P=1.973×10-6;
adjusted: P=4.347×10-3
rs79087668 T 0.20% (10) 0.32% (25) 0.617 0.999 0.20% (13) 0.0030 (29) 0.364 4.44×10-2 
unadjusted:P=1.693×10-9;
adjusted: P=1.367×10-3
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Custom content single variant association analysis 
After exclusions, 3226 case samples, 3262 controls and 2489 SNPs were included in the custom 
content analyses of COPD risk and severity of airflow limitation. The strongest signal identified in 
these analyses was for an association with COPD risk at the previously reported 15q25 region 
(rs2036527 near CHRNA5, Supplementary Figure 9 and Supplementary Table 6). There were two 
additional SNPs within the 15q25 region showing association with COPD risk; conditional analyses 
confirmed that these did not represent an independent signal to the sentinel SNP (Supplementary 
Table 7). Although an additional four SNPs showed association (P<10-3) with COPD risk and 5 SNPs 
showed association (P<10-3) with severity of airflow obstruction in cases (Supplementary Figure 10 
and Supplementary Table 8), none were further replicated in the UK BiLEVE study. 
Supplementary Figure 9: A) Custom content analysis of COPD risk, with pack-years adjustment (SNPs with P<10-3 
highlighted). B) Custom content analysis of COPD risk, without pack-years adjustment ( SNPs with P<10-3 highlighted). 
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Supplementary Figure 10: A) Custom content analysis of severity of airway limitation, with pack-years adjustment (SNPs 
with P<10-3 highlighted). B) Custom content analysis of severity of airway limitation, without pack-years adjustment ( 
SNPs with P<10-3 highlighted). 
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Supplementary Table 6: Top associations (P<10-3) from custom content analyses of COPD risk, with and without adjustment for pack-years smoking and replication in UK BiLEVE. 
Discovery pack-years 
adjusted analysis (2517 
cases, 2252 controls) 
Discovery unadjusted analysis 
(3226 cases, 3262 controls) 
UK BiLEVE  pack-years adjusted analysis (4231 
cases, 8979 controls) 
rs no. CHR Position Coded 
Allele 
Gene MAF 
(MAC) 
OR P* MAF 
(MAC) 
OR P* Imputation 
quality (R2) † 
MAF 
(MAC) 
OR P* 
rs7549174 1 28319484 G 
EYA3 
(intronic) 
30.8% 
(2934) 
0.8066 1.27×10-3 
31.0% 
(4023) 
0.8375 9.68×10-4 0.993 
31.0% 
(8183) 
1.0133 0.665 
rs4622901 3 132697086 A 
near 
TMEM108 
(intergenic) 
34.5% 
(3290) 
0.8021 5.86×10-4 
35.4% 
(4588) 
0.8618 3.83×10-3 0.999 
36.0% 
(9504) 
0.9903 0.740 
rs10957070 8 59712593 G 
near TOX 
(intergenic) 
26.3% 
(2504) 
1.212 6.21×10-3 
25.9% 
(3364) 
1.212 7.45×10-4 0.989 
25.9% 
(6833) 
0.9884 0.717 
rs2036527 15 78851615 A 
near 
CHRNA5 
(intergenic) 
31.5% 
(3006) 
1.38 4.94×10-7 
35.3% 
(4581) 
1.338 2.22×10-8 0.995 
34.8% 
(7631) 
1.029 0.077 
rs2510527 21 31577206 A 
near CLDN8 
(intergenic) 
5.9% 
(560) 
0.6431 6.86×10-4 
5.8% 
(752) 
0.7541 7.41×10-3 0.997 
5.7% 
(1495) 
0.9901 0.870 
*P-values in bold significant at P<10-3 level 
†SNPs which were directly genotyped have imputation quality of NA. 
Supplementary Table 7: Risk of COPD associations within CHRNA5 region (Custom content analysis signals rs8042238 and rs569207), conditional on rs2036527. 
Risk of  COPD with pack-years adjustment Unadjusted  analysis of risk of  COPD 
Single SNP 
association 
Association 
conditional on 
rs2036527 
Single SNP 
association 
Association 
conditional on 
rs2036527 
rs no. OR P OR P OR P OR P
rs8042238 0.8168 1.63×10-3 0.934 0.345 0.8351 4.64×10-4 0.939 0.277 
rs569207 0.768 5.79×10-3 0.867 0.083 0.7937 1.86×10-4 0.885 0.065 
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Supplementary Table 8:Top associations (P<10-3) in custom content analysis of severity of airflow limitation, with and without adjustment for pack-years smoking and replication in UK 
BiLEVE. 
Severity of  airflow limitation, 
adjusted for pack-years (n=2517) 
Unadjusted  analysis of severity of 
airflow limitation (n=3226) 
UK BiLEVE  pack-years adjusted analysis (4231 
cases, 8979 controls) 
rs no. CHR Position 
Coded 
Allele
Gene 
MAF 
(MAC)
Beta P*
MAF 
(MAC)
Beta P*
Imputation 
quality (R2) † 
MAF 
(MAC) 
Beta P* 
rs7816350 8 126289605 G 
NSMCE2 
(intronic) 
12.1% 
(611) 
2.40 8.93×10-4 
12.0% 
(773) 
1.59 1.42x10-2 
NA 11.5% 
(974) 
0.006 0.9879 
rs12235542 9 125234354 A OR1J2 (intronic) 
44.8% 
(2254) 
1.57 8.65×10-4 
44.8% 
(2887) 
1.53 2.87×10-4 
0.979 45.0% 
(3811) 
-0.021 0.3349 
rs1923394 10 4307011 A 
near LINC00702 
(intergenic) 
15.7% 
(792) 
2.23 7.01×10-4 
16.0% 
(1033) 
1.95 8.01×10-4 
0.982 15.6% 
(1320) 
-0.0547 0.0667 
rs1220574 13 24757444 A 
SPATA13 
(intronic) 
0.02% (1) -41.93 1.26×10-2 0.05% (3) -32.67 8.34×10-4 
0.557 0.16% 
(14) 
0.411 0.2538 
rs1705662 14 84282660 A intergenic 
15.8% 
(795) 
2.38 2.72×10-4 
15.6% 
(1006) 
1.55 8.23×10-3 
0.990 15.6% 
(1270) 
0.0233 0.4365 
*P-values in bold significant at P<10-3 level 
†SNPs which were directly genotyped have imputation quality of NA. 
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